What is the role of antibody testing in the workup of multifocal motor neuropathy (MMN) with conduction block?

Updated: Nov 12, 2018
  • Author: Sasa Zivkovic, MD, PhD; Chief Editor: Nicholas Lorenzo, MD, MHA, CPE  more...
  • Print

Most studies report elevated titers of anti-GM1 antibodies in 50% of patients with multifocal motor neuropathy (MMN), but values and sensitivity depend on the methodology. Very high titers of anti-GM1 antibodies (>1:6400) have 80% specificity for MMN, but only 20-30% of patients with MMN have titers of 1:1800 and higher. Lower titers (1:400-800) are less specific and can be found with other neuropathies and amyotrophic lateral sclerosis (ALS).

Clinical features of MMN patients with high titers of anti-GM1 antibodies are typically indistinguishable from patients with negative titers.

The variable sensitivity of different methods of measuring anti-GM1 antibodies is well described. The highest yields and sensitivity of up to approximately 90% have been reported with covalent enzyme-linked immunosorbent assay (ELISA) methodology, while some commercially available assays for anti-GM1 antibodies may have sensitivity that is as low as 20-30%.

The sensitivity of testing may be further increased by adding anti-GM1/galactocerebroside antibodies, although this test may still not be available through commercial laboratories. [17]

Other autoantibodies

Various studies showed elevated titers of other antibodies in MMN including NS6S, neurofascin-186, and gliomedin antibodies. [18, 19] Clinical significance of these antibodies is still not well understood, and these assays are not widely comercially available.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!